Skip to content
Screener

IDEAYA Biosciences, Inc. IDYA Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Amgen logo
AmgenAMGN
$95.64B+8.8%
WHW
Whitehawk TherapeuticsWHWK
$127.23M-45.6%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$137.68M-11.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$435.79M+58.9%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
$850.83M

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,856,154 and 87,796,561 shares issued and outstanding as of March 31, 2026 and December 31, 202599
Additional paid-in capital1,772,8301,757,197
Accumulated other comprehensive (loss) income(494)2,267
Accumulated deficit(835,078)(736,539)
Total stockholders’ equity937,2671,022,934
Total liabilities and stockholders’ equity$1,030,348$1,109,324

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s total liabilities & equity?
IDEAYA Biosciences, Inc. (IDYA) reported total liabilities & equity of $1.03B in Q1 2026.
How has IDEAYA Biosciences, Inc.'s total liabilities & equity changed year-over-year?
IDEAYA Biosciences, Inc.'s total liabilities & equity decreased by 6.4% year-over-year, from $1.1B to $1.03B.
What is the long-term trend for IDEAYA Biosciences, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s total liabilities & equity has grown at a 30.0% compound annual growth rate (CAGR), from $298.27M to $1.11B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about IDEAYA Biosciences, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude